stockportfolio.pro
Altimmune, Inc. (ALT)
Healthcare · Biotechnology · NasdaqGM
Altimmune, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.24M | $10.74M | $10.33M | $5.80M | $8.19M | $4.41M | $-68,000 | $426,000 | $20,000 | $41,000 |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | $-11.09M | $-46.43M | $-39.17M | $-20.52M | $-49.04M | $-97.09M | $-84.71M | $-88.45M | $-95.06M | $-88.09M |
| Net margin | -342.6% | -432.3% | -379.2% | -353.7% | -599.2% | -2201.6% | 124577.9% | -20762.2% | -475295.0% | -214861.0% |
Source: Altimmune, Inc. SEC filings (10-K). 16 years of history available in the interactive view.
Explore 16 years of Altimmune, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track ALT in your portfolio →
Altimmune, Inc. financial history by metric
About Altimmune, Inc.
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Altimmune, Inc. — frequently asked questions
What is Altimmune, Inc.'s revenue?
Altimmune, Inc. (ALT) reported revenue of $41,000 for fiscal year 2025, up 105.0% from the prior year, according to its SEC filings.
Is Altimmune, Inc. profitable?
No — ALT reported a net loss of $-88.09M in fiscal 2025.
What is ALT's P/E ratio?
Altimmune, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Altimmune, Inc. growing?
ALT's revenue grew at roughly -65.3% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Altimmune, Inc. have?
As of fiscal year 2025, ALT carried roughly $34.29M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Altimmune, Inc.'s market cap?
Altimmune, Inc. (ALT) has a market capitalization of about $508.55M, based on the latest data in our nightly-refreshed cache.
When does Altimmune, Inc.'s fiscal year end?
ALT's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Altimmune, Inc.'s official SEC filings (10-K and 10-Q), covering 16 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.